期刊
DIAGNOSTICS
卷 12, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics12030627
关键词
amyloidosis; immunoglobulin light chain amyloidosis; transthyretin amyloidosis; multimodal imaging; biomarkers
资金
- National Research Foundation of Korea (NRF) - Ministry of Science and ICT [NRF-2021R1F1A1063430, NRF-2021R1G1A1007523]
- Catholic Medical Center Research Foundation
- Korean Society of CardioMetabolic Syndrome
This article summarizes the role of multimodal imaging and biomarkers in the diagnosis, risk stratification, and treatment monitoring of cardiac amyloidosis.
Amyloidosis is a progressive infiltrative disease instigated by the extracellular deposition of amyloid fibrils in various organs such as the heart, kidney, and peripheral nerves. Cardiac amyloid deposits cause restrictive cardiomyopathy, leading to a poor prognosis in systemic amyloidosis. The most common etiologies of cardiac amyloidosis (CA) are immunoglobulin light chain deposits (AL-CA) and misfolded transthyretin deposits (ATTR-CA). In recent years, many developments have been accomplished in the field of diagnosis and treatment of CA. At present, ATTR-CA can be noninvasively diagnosed if the following two conditions are fulfilled in the setting of typical echocardiographic /cardiac MRI findings: (1) grade 2 or 3 myocardial uptake in bone scintigraphy confirmed by SPECT and (2) absence of monoclonal protein confirmed by serum-free light chain assay, and serum/urine protein electrophoresis with immunofixation test. Effective therapies are evolving in both types of CA (tafamidis for ATTR-CA and immunologic treatments for AL-CA). Thus, early suspicion and prompt diagnosis are crucial for achieving better outcomes. In this review, we have summarized the role of multimodal imaging (e.g., echocardiography, cardiac MRI, and bone scintigraphy) and biomarkers (e.g., troponin, BNP) in the diagnosis, risk stratification, and treatment monitoring of CA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据